Reference intervals of urinary acute kidney injury (AKI) markers [IGFBP7]∙[TIMP2] in apparently healthy subjects and chronic comorbid subjects without AKI  by Chindarkar, Nandkishor S. et al.
Clinica Chimica Acta 452 (2016) 32–37
Contents lists available at ScienceDirect
Clinica Chimica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /c l inch imReference intervals of urinary acute kidney injury (AKI) markers
[IGFBP7]∙[TIMP2] in apparently healthy subjects and chronic comorbid
subjects without AKINandkishor S. Chindarkar a, Lakhmir S. Chawla b, Joely A. Straseski c, Saeed A. Jortani d,
Denise Uettwiller-Geiger e, Robert R. Orr f, John A. Kellum g, Robert L. Fitzgerald a,⁎
a Department of Pathology, Center for Advanced Laboratory Medicine, University of California—San Diego Health Systems, San Diego, CA, United States
b Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, Washington, DC, United States
c Department of Pathology and ARUP Laboratories, University of Utah School of Medicine, Salt Lake City, UT, United States
d Department of Pathology, University of Louisville, Louisville, KY, United States
e John T. Mather Memorial Hospital, Port Jefferson, NY, United States
f Phoenix Medical Group, Peoria, AZ, United States
g Center for Critical Care Nephrology Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, United StatesAbbreviations: AKI, acute kidney injury; IGFBP7, insu
protein 7;; KDIGO, kidney disease improving global
gelatinase-associated lipocalin; TIMP-2, tissue inhibitor of
⁎ Corresponding author at: Center for Advanced Labo
California—San Diego, 10300 Campus Point Drive, Sui
United States.
E-mail address: rﬁtzgerald@ucsd.edu (R.L. Fitzgerald).
http://dx.doi.org/10.1016/j.cca.2015.10.029
0009-8981/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 2 July 2015
Received in revised form 26 October 2015
Accepted 27 October 2015
Available online 10 November 2015
Keywords:
Acute kidney injury
Cell-cycle arrest
Insulin-like growth factor-binding protein 7
(IGFBP7)
Nephrocheck
Reference interval
Tissue inhibitor of metalloproteinases-2
(TIMP-2)Background: Insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2
(TIMP-2) have demonstrated signiﬁcantly improved diagnostic performance in assessing risk for acute kidney
injury (AKI) compared with existing biomarkers. We present the ﬁndings of a multi-site trial to determine the
reference intervals for these biomarkers in apparently healthy adults and those with stable chronic morbid
conditions without AKI.
Methods: A urine specimen was collected from apparently healthy subjects (N= 378) and subjects with at least
one stable chronic morbidity (N= 372). Specimens were kept frozen until analysis with the NEPHROCHECK® Test
(Astute Medical). The test is comprised of ﬂuorescence immunoassays for IGFBP7 and TIMP-2 and is used with
the ASTUTE140® Meter which quantiﬁes the concentration of each biomarker. The meter multiplies the concen-
trations of IGFBP7 and TIMP-2 and displays the result as a numerical value ([IGFBP7]∙[TIMP-2]) expressed in
(ng/ml)2/1000 which is called the AKIRISK™ Score.
Results: The reference intervals (inner 95%) for [IGFBP7]∙[TIMP-2] in all subjects (N = 750), apparently healthy
subjects, and subjects with stable chronic morbidities were 0.04–2.22, 0.04–2.25, and 0.05–2.20 (ng/ml)2/1000
respectively. There was no statistical difference between reference intervals for apparently healthy and chronic
stable morbid cohorts (p = 0.42).
Conclusions: Our investigation showed that urine [IGFBP7]∙[TIMP-2] values were not elevated in patients with
stable chronic morbidities who did not have AKI.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Acute kidney injury (AKI) is a disease with multiple etiologies that
lacks an effective speciﬁc treatment in current clinical practice [1]. Var-
ious exposures (e.g., infections, medications, toxins) can cause kidneylin-like growth factor-binding
outcomes; NGAL, neutrophil
metalloproteinases-2.
ratory Medicine, University of
te 150, San Diego, CA 92121,
. This is an open access article underdamage leading to AKI, which results in rapid loss of function. AKI can
lead to a temporary or permanent loss of kidney function or even
death. AKI substantially increases mortality, morbidity, length of hospi-
talization, adverse long term health consequences, and the cost of
healthcare [2,3]. The annual death rate from AKI is higher than breast
cancer, prostate cancer, and heart failure combined [4]. Irreversible kid-
ney failure might be preventable if biomarkers can identify AKI early in
the disease process [5–7]. Ideally, AKI biomarkers should be sensitive
and speciﬁc. In order to change patient outcome they should be able
to identify AKI early in the disease process in an easily accessible matrix
(e.g., urine). In reality, it is difﬁcult to ﬁnd such biomarkers and no pre-
viously described biomarkers possess all of these characteristics [8].
Recently, Kashani et al. reported insulin-like growth factor-binding
protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Inclusion and exclusion criteria for chronic stable morbid subjects.
An individual of age ≥21 y andwith any one ormore of the following chronic, stable, mor-
bid conditions (in addition to meeting the exclusion criteria), was classiﬁed as ‘chronic,
stable, morbidity subject’.
Inclusion criteria (morbidities)
− Hypertension
− Osteoarthritis
− Coronary artery disease
− Gout
− Congestive heart failure
− Diabetes mellitus (type 1 or 2)
− Arrhythmia (atrial ﬁbrillation, heart
block, ventricular tachycardia)
− Hyperlipidemia (includes hyper-
cholesterolemia)
− Hyper- or hypothyroidism
− Chronic obstructive pulmonary dis-
ease (including emphysema chronic
bronchitis, and asthma)
− Neuromuscular disease
− Immunocompromised
− Liver cirrhosis
− Rheumatoid arthritis
− Hepatic failure
− Systemic lupus erythematosus
− Inﬂammatory bowel disease (in-
cluding Crohn's disease and ulcera-
tive colitis)
− Chronic coagulation abnormality
− Any active cancer
− Bladder, prostate, or renal cell cancer
− Chronic pancreatitis
− Chronic renal insufﬁciency
− Cancer affecting kidney function
− Other kidney disease including
polycystic kidney disease
Exclusion criteria
− Subject with any known or
suspected acute illness or condition
- including acute infections — at the
time of enrollment or within the
previous 30 days
− Subject with any new onset or
unstable morbidities
− Subject with any trauma-related
surgery within the last 6 months
− Subject with any surgery, hospitali-
zation or institutionalization (such
as in a nursing home) during the
previous 3 months
− Subject who received any blood
product transfusion within the
previous 2 months
− Subject who was a pregnant
woman or child
− Subject who was a prisoner or in-
stitutionalized individual
− Subject who has previously enrolled
in this study
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ed that elevation of IGFBP7 and TIMP-2 are predictive of the develop-
ment of moderate to severe AKI [kidney disease improving global
outcomes (KDIGO) stage 2 to 3] within 12 h of specimen collection
[10]. These 2 biomarkers performed better than previously identiﬁed
biomarkers such as kidney injury marker-1 (KIM-1), neutrophil
gelatinase associated lipocalin (NGAL), cystatin-C, interleukin-18,
pi-glutathione S-transferase, and liver fatty acid-binding protein. A sub-
sequent multi-site international study (Topaz) using identical entry
criteria which also used clinical adjudication for AKI endpoints, con-
ﬁrmed that these biomarkers can identify patients at high risk for immi-
nent AKI [11].
IGFBP7, also known as Mac25, tumor adhesion factor (TAF), pros-
tacyclin stimulating factor (PSF), and IGFBP-rP1 belongs to the IGFBP
family. IGFBP7 has been hypothesized to have a signiﬁcant biological
role in cell proliferation, apoptosis, and senescence [12–14]. TIMP-2
is a member of the matrix metalloproteinase family that has been
shown to mediate both tissue development and remodeling [15].
Both IGFBP7 and TIMP-2 have been implicated in G1 cell-cycle arrest
[16–18]. For short periods of time, cell cycle arrest is likely protec-
tive, preventing cells from entering cell cycle during periods of im-
minent or current injury [19]. However, when cell cycle arrest is
prolonged, cells can transition to a ﬁbrosis phenotype. Studies of
AKI demonstrated the role of prolonged cell cycle arrest in the tran-
sition of AKI to CKD [20]. Early on, activation of these cell cycle arrest
markers function as an alarm signal, indicating something is wrong.
The time window for cell cycle arrest activation to be protective is
likely brief, and sustained cell cycle arrest can be maladaptive. An
analogy would be cortisol activation during stress. In the short-
term, this response is protective, but sustained cortisol stimulation
is linked to increased morbidity. In the case of cell-cycle arrest, the
harm may come from cell senescence (a phenotype in which the
cells can never re-enter cell division and in which ﬁbroblasts rather
than new epithelial cells are attracted to close gaps in renal tubular
epithelium) which may lead to CKD.
This is the ﬁrst report of the observed values (reference interval)
of [IGFBP7]∙[TIMP-2] in urine where a large group of subjects includ-
ing apparently healthy individuals and individuals with stable
chronic morbidities were studied in order to determine how these
biomarkers varied in different patient populations that were not
acutely ill and did not have signs or clinical ﬁndings of AKI.2. Materials and methods
2.1. Study design and study participant selection
The protocols for this investigation were approved by investiga-
tional review boards/ethics committees as required by each partici-
pating institution. All subjects provided written informed consent.
Subjects of ≥21 y age, who provided written informed consent for
the study participation, and met the morbidity criteria (Table 1)
were selected in the stable chronic morbidity cohort. A listing of
the morbid conditions and number of subjects with each condition
is shown in Table 1 of Chindarkar et al. [21]. For apparently healthy
subjects, individuals of ≥21 y, who provided written informed con-
sent for study participation, and met the healthy criteria (Table 3 of
Chindarkar et al. [21]), were selected for this cohort. The urine spec-
imens were collected at 6 geographically diverse sites (Rochester,
NY; Dallas, TX; Gresham, OR; Springﬁeld, MO; Layton, UT; Peoria,
AZ). The specimen collected from each subject was split into three al-
iquots and frozen (−80 °C) within 120 min of collection. The frozen
specimens were shipped to 3 different testing sites for analysis (Uni-
versity of California at San Diego; University of Louisville; ARUP Lab-
oratories). Specimens were collected over the time frame of April
2012 to November 2012.2.2. Demographic characteristics
A total of 379 and 373 subjects were enrolled in the apparently
healthy and stable chronic morbidity cohorts respectively (Fig. 1). One
subject was excluded from each cohort to give a total of 750 subjects.
The two subjects were excluded because specimens from these subjects
were processed outside the allowable time window of 120 min of col-
lection. Demographic characteristics of the 750 subjects selected for
this study are described in the Table 2. The target demographic distribu-
tion used in this study is provided in the Table 3 of Chindarkar et al. [21].
This distribution was targeted to reﬂect the general demographic data
for United States intensive care units.2.3. Biomarker measurement
The NEPHROCHECK® Test is an FDA cleared [22] in-vitro diagnostic test
that quantitatively measures IGFBP7 and TIMP-2 in human urine on the
ASTUTE140®Meter, a bench/table-top analyzer [23]. It is a single-use car-
tridge comprised of sandwich immunoassays for IGFBP7 and TIMP-2 on
a membrane test strip enclosed in a plastic housing. The ASTUTE140®
Meter converts the ﬂuorescent signal from each of the 2 immunoassays
(IGFBP7 and TIMP-2) contained within the NEPHROCHECK® Test cartridge
into a single numerical result called the AKIRISK™ Score. The AKIRISK™
Score i.e. [IGFBP7]∙[TIMP-2] is calculated as the product of themeasured
concentrations of the 2 biomarkers, IGFBP7 and TIMP-2 (in (ng/ml)2),
divided by 1000. The test result ([IGFBP7]∙[TIMP-2]) is displayed with-
out units. The limit of blank, limit of detection, limit of quantitation
and reportable range for [IGFBP7]∙[TIMP-2] were 0.0002, 0.002, 0.002,
and 0.04–10.0 respectively [23]. Concentrations of IGFBP7 and TIMP-2
are traceable to reference standards as described by ISO 17511 [5].
Each single use cartridge includes a built in positive and negative con-
trol. If the automatic check of these internal controls shows that the
Fig. 1. Reference interval subjects selection, specimen collection, and analysis. All selected
specimenswere subjected to analysis byNEPHROCHECK® Test andASTUTE140®Meter. (* One
subject was excluded for protocol deviation).
Table 2
Demographic characteristics of apparently healthy and chronic stable morbidity cohorts.
Apparently healthy cohort
(N = 378)
Chronic stable morbidity
cohort (N = 372)
Variable/stratum N, mean, or
median
%, SD, or IQR N, mean, or
median
%, SD, or IQR
Sex
Female 191 (50.5) 191 (51.3)
Male 187 (49.5) 181 (48.7)
Race
American Indian 3 (0.8) 6 (1.6)
Asian 9 (2.4) 10 (2.7)
Black/African 43 (11.4) 43 (11.6)
Amer.
Native 1 (0.3) 3 (0.8)
Hawaiian
Caucasian 313 (82.8) 300 (80.6)
Unknown 0 (0.0) 0 (0.0)
Other 9 (2.4) 10 (2.7)
Ethnicity
Hispanic 43 (11.4) 33 (8.9)
Non-Hispanic 335 (88.6) 339 (91.1)
Age (years)
Mean (SD) 54 (17.3) 63 (14.7)
Median (IQR) 56 (40–68) 65 (53–75)
Height (cm)
Mean (SD) 169.5 (9.87) 168.2 (10.17)
Median (IQR) 170.0 (162.6–177.8) 167.6 (160.0–175.3)
Weight (kg)
Mean (SD) 78.8 (18.74) 87.0 (21.93)
Median (IQR) 77.0 (65.6–86.9) 84.3 (71.6–99.2)
BMI (kg/m2)
Mean (SD) 27.5 (5.87) 30.8 (7.02)
Median (IQR) 26.8 (23.3–29.8) 29.8 (26.2–34.5)
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display an error message and the test result will not be reported. In ad-
dition, external liquid and electronic quality controls were used to en-
sure proper functioning of each ASTUTE140® Meter used for specimen
analysis. Two external liquid controls (low and high concentrations)
were analyzed once on each meter when they were initially put into
use to verify test performance and operator proﬁciency. IGFBP7 and
TIMP-2 concentrations in the high control were 419.3 and 127.6 ng/ml
respectively while in low control they were 61.2 and 3.1 ng/ml respec-
tively. Liquid control results were acceptable if they werewithin±2 SD
of the expected concentrations. An external electronic control was run
on each meter every day prior to the specimen analysis. The external
electronic control procedure veriﬁes the calibration of the ASTUTE140®
Meter, including the positioning system, optical system and other inter-
nal systems of the meter to conﬁrm that the meter is functioning
properly.
Frozen specimenswere thawed at room temperature (18–25 °C) in a
water bath for a thawing timenot exceeding 20min. Once the specimen
was thawed, it was gently inverted 1–2 times to ensure uniformmixing
and was immediately tested. The specimen was loaded into a
NEPHROCHECK® Test cartridge within one hour of placing the specimen
into the water bath. A 100 μL aliquot of the buffer supplied with the
assay kit was added to a labeled ﬂuorescent conjugate vial followed byaddition of a 100 μl aliquot of thawed urine specimen. The solution
was mixed gently. The mixture (100 μl) was then loaded onto a
NEPHROCHECK® Test cartridge. The test cartridge was loaded onto the
ASTUTE140® Meter which provides results in 20 min. [IGFBP7]∙[TIMP-2]
value was displayed on the ASTUTE140® Meter screen after the
NEPHROCHECK® Test procedure was completed.2.4. Statistics
Reference intervals were deﬁned as the inner 95th percentile of
the rank ordered data [24,25]. The intervals were determined by
sorting NEPHROCHECK® Test results (from 3 testing sites) from low to
high, and then using the CEIL function in SAS ver 9.2 [SAS Institute
Inc.] to determine the rank corresponding the percentile of interest
[rank for the low end of reference interval = CEIL (0.025 ∗ N), rank
for the high end of reference interval = CEIL (0.975 ∗ N), where
N = total number of specimens]. The test values corresponding to
the ranks are the values for the reference interval. The distributions
of [IGFBP7]∙[TIMP-2] values from the apparently healthy and stable
chronic morbidity cohorts were compared using the Kolmogorov–
Smirnov test. We used log-linear analysis to test null hypotheses of
independence between the reference interval ([IGFBP7]∙[TIMP-2]
values below, within, and above the inner 95%), study cohort (appar-
ently healthy or stable chronic morbidity), and sex [26]. Because
there were multiple [IGFBP7]∙[TIMP-2] test results per sample, a per-
mutation test was used to calculate p-values. Two-sided p b 0.05
were considered statistically signiﬁcant. Statistical tests were per-
formed using R 3.0.1 [27]. To assess associations between mean
[IGFBP7]∙[TIMP-2] values and age, we calculated Spearman's rank
correlation coefﬁcient (rs) within each cohort. For the precision
studies, the method described by Rodbard et al. was used to deter-
mine the CV within each tertile [28].
Table 3
Rank ordered percentile for [IGFBP7]∙[TIMP-2] values in all 750 subjects.
Percentile
Population Male/female Subjects Specimensa Reference intervalb 2.5 5 10 25 50 75 90 95 97.5
All Both 750 2246c 0.04–2.22 0.04 0.05 0.07 0.14 0.33 0.73 1.29 1.77 2.22
Apparently healthy subjects Both 378 1132 0.04–2.25 0.04 0.05 0.07 0.14 0.32 0.74 1.29 1.85 2.25
Chronic stable morbidity subjects Both 372 1114 0.05–2.20 0.05 0.06 0.07 0.13 0.34 0.72 1.29 1.75 2.20
Apparently healthy subjects Female 191 573 0.04–2.24 0.04 0.04 0.06 0.12 0.29 0.68 1.28 1.79 2.24
Male 187 559 0.04–2.25 0.04 0.05 0.09 0.17 0.36 0.77 1.33 1.88 2.25
Chronic stable morbidity subjects Female 191 573 0.04–2.15 0.04 0.05 0.06 0.13 0.36 0.76 1.29 1.76 2.15
Male 181 541 0.06–2.23 0.06 0.07 0.08 0.13 0.33 0.70 1.24 1.69 2.23
Note: 48% of the [IGFBP7]∙[TIMP-2] values were ≤0.3 and 96% were ≤2.0). [IGFBP7]∙[TIMP-2] are expressed in (ng/ml)2/1000
a A specimen from each subject was divided into three aliquots. Aliquots were tested at three independent hospital laboratories.
b Based on 2.5% and 97.5% values in sets of at least 120 subjects.
c Total number of specimenswas 2250 (750 × 3) but 4 specimenwere not includeddue to 2 specimenhandling protocol deviations, 1 invalid result thatwas erroneously not retested as
speciﬁed in the protocol, and 1 shipment error.
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Of the 750 subjects selected for this study, 378 were categorized as
apparently healthywhile 372were categorized as subjects with chronic
stable morbidities but no AKI. The distributions of all [IGFBP7]∙[TIMP-2]
values from the apparently healthy and chronic stable morbidity co-
horts are shown in Fig. 2. Therewas no statistically signiﬁcant difference
between the distributions of these cohorts (p=0.62). The overall refer-
ence interval of [IGFBP7]∙[TIMP-2] for the entire population studied
(N = 750) was 0.04–2.22 (Table 3). Reference intervals for apparently
healthy (N = 378) and chronic stable morbid (N = 372) subjects
were 0.04–2.25 and 0.05–2.20, respectively. There was no statistically
signiﬁcant difference between these reference intervals (p=0.42). Fur-
ther stratiﬁcation of the cohorts by sex (male or female) did not signif-
icantly affect the reference interval (p=0.14 for the test of dependence
of the reference interval on cohort and sex). Within the apparently
healthy cohort, the reference intervals for males and females were
0.04–2.25 (N = 187) and 0.04–2.24 (N = 191), respectively. Within
the chronic stable morbidity cohort, the reference intervals for males
and females were 0.06–2.23 (N = 181) and 0.04–2.15 (N = 191),
respectively. As shown in Fig. 3, there was a weak inverse correlation
between mean [IGFBP7]∙[TIMP-2] value and age in both cohorts
(rs = −0.13, p = 0.014, within the apparently healthy cohort, and
rs =−0.11, p = 0.038, within the chronic stable morbidity cohort).
To demonstrate the consistency of results obtained at three different
testing laboratories, we calculated the inter-laboratory precision (% CV)
of [IGFBP7]∙[TIMP-2] measurements (Table 4). A urine specimen from
each qualifying subject was analyzed in singlicate at the three sites.
We used the average of all [IGFBP7]∙[TIMP-2] values for each subjectFig. 2. [IGFBP7]∙[TIMP-2] distribution in apparently healthy (graand split the concentration range into tertiles in order to demonstrate
precision at the low, medium and high concentrations of test results.
The inter-laboratory CV was 10% or less within each tertile.
Serum creatinine, serum urea, and urine output are conventional
biomarkers of kidney function [29–32] and as such have limitations
for prognosticating risk of renal injury. By deﬁnition, loss of kidney func-
tion indicates renal injury, which causes the end products of nitrogen
metabolism (e.g. urea and creatinine) to accumulate in circulation.
When measured in a serial manner, small increases of creatinine,
≥0.3 mg/dl over 48 h, deﬁne AKI [10], but at this point renal injury has
occurred. In comparison, [IGFBP7]∙[TIMP-2] are not indicators of renal
function, rather they indicate early signs of renal stress, thus they ap-
pear to be fundamentally different than renal function biomarkers.
[IGFBP7]∙[TIMP-2] are more appropriately used to evaluate risk of
renal injury as opposed to documenting decline in function.
Among the previously described biomarkers for AKI, NGAL has been
extensively investigated [33–36]. Since its discovery [36], NGAL has
shown better predictive and diagnostic value compared to creatinine
and has been considered a promising biomarker of AKI. NGAL showed
excellent sensitivity and speciﬁcity in pediatric patients in predicting
AKI after cardiac surgery [35]. However, a primary limitation of this bio-
marker is that its concentration may rise in the setting of chronic and
acute inﬂammatory conditions frequently encountered in the ICU pa-
tients [33,34]. NGAL is also expressed by tissues other than the kidney
[37].
For patients at risk for AKI in the immediate future, the goal is to de-
tect AKI as early as possible. Early detection gives clinicians time to con-
sider various treatment and/or management options. If a patient is at
high risk for AKI, a more conservative treatment approach can bey bars) and chronic morbid (no AKI) subjects (solid bars).
Fig. 3. [IGFBP7]∙[TIMP-2] values by age range for (A) apparently healthy subjects and
(B) subjects with chronic stable morbidities. Boxes and whiskers show interquartile
ranges and 5th to 95th percentiles, respectively. Horizontal dashes within the boxes
show median values.
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Studies from Kashani et al. [9] and Bihorac et al. [11] demonstrated that
early detection of AKI is possible with the help of IGFBP7 and TIMP-2.
These authors reported that elevated concentrations of IGFBP7 and
TIMP-2 predict AKI within 12 h of becoming elevated. The study by
Kashani and colleagues involved 744 critically ill patients, including
those with acute illnesses such as sepsis (but without a diagnosis of
AKI at enrollment), to see how these 2 biomarkers perform compared
to othermarkers. All patients enrolled in this studywere in the intensive
care unit and expected to be there for at least 48 h. Comparison of
IGFBP7 and TIMP-2 with existing biomarkers based on area under
receiver-operating characteristic curve (AUC) revealed that together
IGFBP7 and TIMP-2 (AUC of 0.8) performed signiﬁcantly better than
other biomarkers. It was observed that the risk of AKI within 12 h
increased sharply when [IGFBP7]∙[TIMP-2] values were N0.3 and quin-
tupled when N2.0 [9].
Recently Hoste et al. veriﬁed 0.3 and 2.0 cutoff values for
[IGFBP7]∙[TIMP-2] in 154 critically ill patients [6]. A high sensitivity
(89%) cutoff of 0.3 was chosen in order to identify any patients who
were at increased risk for AKI within 12 h of assessment. This cutoff
had a 97% negative predictive value and indicated a low probability of
AKI when the patient tested at or below this cutoff. The second cutoff
of 2.0 had high speciﬁcity (N90%) and indicates patients with a veryTable 4
Inter-laboratory percent CV of [IGFBP7]∙[TIMP-2] values obtained from 3 independent
hospital laboratories on 750 subjects. A specimen was collected from each subject and
divided into three aliquots. Each testing site received an aliquot from each subject. The
average [IGFBP7]∙[TIMP-2] values were rank ordered and divided into tertiles. The inter-
laboratory CV within each tertile is shown below.
Tertile [IGFBP7]∙[TIMP-2] in (ng/ml) 2/1000 % CV
1st 0.04–0.18 9
2nd 0.19–0.57 10
3rd 0.58–7.18 9high risk of developing AKI within 12 h. The authors report that the
results agree with previous investigation [9] in terms of predicting the
AKI within 12 h of the specimen collection.
Bihorac et al. used a cutoff of 0.3 to identify patients at a risk of devel-
oping AKI in 420 critically ill patients [15]. The 0.3 cutoff had a sensitiv-
ity and speciﬁcity of 92% and 46%, respectively. Patients developing AKI
within 12 h had a median (interquartile range [IQR]) urinary
[IGFBP7]∙[TIMP-2] of 1.6 (0.7–2.8) compared with those without
AKI in which the median (IQR) urinary [IGFBP7]∙[TIMP-2] was 0.3
(0.2–0.8). The authors demonstrated that critically ill patients with uri-
nary [IGFBP7]∙[TIMP-2] N0.3 had 7 times the risk for AKI as compared
with critically ill patients with a test result b0.3.
The median and IQR reported by Bihorac et al. for critically ill pa-
tients without AKI is similar to the median (50th percentile) and IQR
(25th to 75th percentiles) for apparently healthy subjects (0.32 (0.14–
0.74)) and subjects with stable chronic morbidities (0.34 (0.13–0.72))
shown in Table 3. These data conﬁrm that [IGFBP7]∙[TIMP-2] values gen-
erally are not elevated in subjects with common chronic morbidities or
in critically ill patients with acute conditions other than AKI. Signiﬁcant
elevations in [IGFBP7]∙[TIMP-2] values have only been observed in pa-
tients who have or subsequently developed AKI [5,6,9,11]. Although
[IGFBP7]∙[TIMP-2] values are signiﬁcantly increased in AKI patients, ref-
erence intervals in apparently healthy and stable chronic morbid sub-
jects overlap with the values obtained from AKI patients. Reference
interval data show that overall, 50% of the population lies N0.33 and
the rest of the [IGFBP7]∙[TIMP-2] values are ≤0.3 (Table 3). As such,
the [IGFBP7]∙[TIMP-2] values obtained in critically ill patients should
only be used in conjunction with patient condition and clinical signs
and symptoms. This test was developed to assess risk of AKI and not
intended as a sole indicator for the diagnosis of AKI. The primary cutoff
at 0.3 was selected to have high sensitivity to detect the majority of pa-
tients at risk for AKI, with a speciﬁcity near 50%, which is considered ac-
ceptable for the intended use of the test [6]. Our results show this cutoff
falls in themiddle of the reference range, consistent with the speciﬁcity
reported previously in the intended use population [6,11]. Importantly,
this test provides a quantitative result and it is clear from prior work
[3,9] that AKI risk increases with increasing concentrations of
[IGFBP7]∙[TIMP-2]. A secondary, high speciﬁcity (near 95%) cutoff at
2.0 has been reported previously from studies of critically ill patients
[6,11]. Our results show the high end of the reference range is nearly
identical to this secondary cutoff value, consistent with the speciﬁcity
previously reported [6,11]. The KDIGO Guideline recommends kidney
sparingmanagement strategies based on a patient's risk for AKI [10]. Pa-
tients with higher [IGFBP7]∙[TIMP-2] values and the appropriate clinical
presentation are candidates for these management strategies including
increased surveillance, interventions, and therapy adjustments to fur-
ther minimize potential for renal injury.
In summary, the overall reference interval for [IGFBP7]∙[TIMP-2] in
urine is 0.04–2.22. Compared with apparently healthy subjects,
[IGFBP7]∙[TIMP-2] values were not elevated in stable chronic morbid
subjects. This is in contrast with reports for other biomarkers of AKI
such as NGAL, KIM-1, and IL-18which are elevated in a variety of condi-
tions such as liver injury [38], chronic kidney injury [39], and a variety of
other conditions [40], respectively. The cutoff for [IGFBP7]∙[TIMP-2] at
0.3 falls near the middle of the reference interval, consistent with the
speciﬁcity previously validated in critically ill patients. Our data also
conﬁrm that the previously reported high speciﬁcity cutoff of 2.0 has
little overlap with the reference interval and higher values of
[IGFBP7]∙[TIMP-2] are therefore indicative of higher risk of impending
AKI.Acknowledgements
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